France and US.First company outside of the US and Europe to manufacture recombinant human insulin. .INTRODUCTION A pharmaceutical and biotechnology company headquartered in Mumbai. Ireland. -Subsidiaries in US. UK. . India. Ireland and France.Manufacturing plants in India. . UK. -Founded by Habil Khorakiwala in the early 1960s.

SWOT ANALYSIS STRENGTHS ‡ Strong expertise in the area of Recombinant Biotechnology ‡ Strong presence in the European market (50%+ revenue comes from Europe) ‡ Significant ramping up of the US business (with a growth of 50%) ‡ Robust manufacturing infrastructure ‡ Strong insulin portfolio in India .

WEAKNESSES ‡ Less contribution towards revenues by the US business ‡ High debt burden .

OPPORTUNITIES ‡ Leverage on synergies present in the European market ‡ Launch of Glaritus .

THREATS ‡ Integration of European businesses is a major challenge (Negma and Pinewood acquisitions have to be integrated with the UK business) ‡ Pricing pressure in the US may restrict expected revenue growth (price erosion more than 95%) specially in cephalosporin segment. with growing competition from companies like Orchid Chemicals and Lupin ‡ High competition for EPO in regulated markets ‡ Increasing competition in the European generic market with the growing presence of frontline Indian pharma companies including Ranbaxy and Reddys .

and a market capitalisation of over $ 1 billion. . ‡ Wockhardt has revenue of Rs 4.501 crore and operating profit (EBIDTA) at Rs 823 crore during the 15 months period (Jan 2009 ² Mar 2010). the sales revenue was Rs 872 crore and operating profit (EBITDA) was Rs 158 crore. ‡ For the quarter (Jan-March 2010) .MARKET ‡ Annual turnover of US$ 650 million.

‡ Europe Business: Wockhardt UK grew by 19% compared to the industry growth of only 5% in Jan-Mar 2010 over the corresponding period of 2009.GROWTH ‡ India Business: Wockhardt·s India branded business grew by 24% in Jan-Mar 2010 over the corresponding period of 2009. . ‡ USA Business: Wockhardt`s Morton Grove Pharmaceuticals business has shown a robust 40% growth in Jan-Mar 2010 over the corresponding period of 2009.

TOP PRODUCTS DIABETOLOGY Wosulin (Recombinant Insulin ) Mopaday (Oral Antidiabetic) Glimaday (Oral Antidiabetic) PAIN MANAGEMENT: Proxyvon NEURO-PSYCHIATRY Spasmo-Proxyvon NEURO-PSYCHIATRY Libotryp Tryptomer COUGH THERAPY Zedex Bro-Zedex Viscodyne NEPHROLOGY Wepox (Recombinant Erythropoietin) NUTRITION Methycobal Dexolac .

9 41 21.05 +/.38 30.14 0.07 0.41 61.47 % 0.5 23.4 26.31 28.PRODUCT-WISE VALUES PRODUCTS Spasmo-Proxyvon Dexolac Bro-Zedex Magenta Zedex Proxyvon Merideca Wokadine Value in Crores 89.% 7.07 0.07 0.5 36.4 -17.05 0.2 23.06 0.99 30.8 .27 24.9 36.9 -1.21 0.

Azithromycin Tablets. Risperidone Tablets. Nicardipine Injection. Ropinirole HCI Tablets . Divalproex Extended Release Tablets Midazolam HCI Injection. Ranitidine Tablets.NEW LAUNCHES ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ Insulin Glaritus Tamsulosin capsules(Flomax) Amoxicillin Clav K OS.

Reddy's Laboratories Limited Ranbaxy Laboratories Limited .TOP COMPETITORS ‡ ‡ ‡ ‡ ‡ Aurobindo Pharma Limited Cipla Limited Glaxo Smithkline Pharmaceuticals Limited Dr.

Sign up to vote on this title
UsefulNot useful